Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

NEWS 1   Web Page for STN Seminar Schedule – N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
                 substances identified in English–, French–, German–,
                 and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
                 searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
                 coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
                 will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                 Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
                 for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced
NEWS 16 FEB 19 New patent-examiner citations in 300,000 CA/CAplus
                 patent records provide insights into related prior
                 art
NEWS 17 FEB 19 Increase the precision of your patent queries –– use
                 terms from the IPC Thesaurus, Version 2009.01
NEWS 18 FEB 23 Several formats for image display and print options
                 discontinued in USPATFULL and USPAT2
NEWS 19 FEB 23 MEDLINE now offers more precise author group fields
                 and 2009 MeSH terms
NEWS 20 FEB 23 TOXCENTER updates mirror those of MEDLINE – more
                 precise author group fields and 2009 MeSH terms
NEWS 21 FEB 23 Three million new patent records blast AEROSPACE into
                 STN patent clusters
NEWS 22 FEB 25 USGENE enhanced with patent family and legal status
                 display data from INPADOCDB
NEWS 23 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
                 formats
NEWS 24 MAR 11 EPFULL backfile enhanced with additional full-text
                 applications and grants
NEWS 25 MAR 11 ESBIOBASE reloaded and enhanced
NEWS 26 MAR 20 CAS databases on STN enhanced with new super role

```
                    for nanomaterial substances
 NEWS 27  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                    equivalents from China
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced
 NEWS 29  APR 03  CAS coverage of exemplified prophetic substances
                    enhanced


 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
               AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.


 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:38:07 ON 06 APR 2009

=> file reg
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                    ENTRY        SESSION
FULL ESTIMATED COST                                  0.22          0.22

FILE 'REGISTRY' ENTERED AT 07:38:15 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 APR 2009  HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES:   5 APR 2009  HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10551737 R5 aryl R8 and R9 ring.str
```

chain nodes :
7 8 12 13 14 17 19 20
ring nodes :
1 2 3 4 5 6 10 11
chain bonds :
4-17 5-7 7-8 8-20 10-20 11-12 12-13 12-14 17-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11
exact/norm bonds :
4-17 5-7 7-8 10-11 10-20 12-13 12-14 17-19
exact bonds :
8-20 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S

G2:O,S

G3:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 17:CLASS 19:CLASS 20:CLASS

L1   STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1   STR

```
       Cb
        \
        G2

          G1
         /
        /                    N              G2
                                              ‖
                                              G2
```

G1 C,O,S
G2 O,S
G3 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                               ENTRY   SESSION
FULL ESTIMATED COST   0.48   0.70

FILE 'CAPLUS' ENTERED AT 07:38:34 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s L1 SSS full
   REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 07:38:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   184852 TO ITERATE

100.0% PROCESSED   184852 ITERATIONS   65 ANSWERS
SEARCH TIME: 00.00.11

L2   65 SEA SSS FUL L1

L3   4 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1093266 CAPLUS Full-text
DOCUMENT NUMBER: 145:432223
TITLE: Method of treating schizophrenia prodrome
INVENTOR(S):   Woods, Scott W.
PATENT ASSIGNEE(S):   Yale University, USA
SOURCE: PCT Int. Appl., 64pp.
                         CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

      PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
      --------------   ----   --------   -------------------   --------
      WO 2006110724   A2   20061019   WO 2006-US13444   20060411
      WO 2006110724   A3   20070322
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
      AU 2006235400   A1   20061019   AU 2006-235400   20060411
      CA 2602626   A1   20061019   CA 2006-2602626   20060411
      EP 1871165   A2   20080102   EP 2006-740849   20060411
         R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, YU
      JP 2008535864   T   20080904   JP 2008-505637   20060411
PRIORITY APPLN. INFO.:   US 2005-670600P   P   20050411
                                            WO 2006-US13444   W   20060411
OTHER SOURCE(S):   MARPAT 145:432223

AB   The present invention relates to a method of treating schizophrenia prodrome
      in human subjects using a NMDA glycine site agonist, a glycine transporter-1
      inhibitor or mixts. thereof, optionally in combination with a pharmaceutically
      acceptable additive, carrier or excipient.
IT   791642-83-6
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
          (method of treating schizophrenia prodrome with NMDA glycine agonist
          and glycine transporter-1 inhibitor)
RN   791642-83-6 CAPLUS
CN   L-Proline, 1-[2-[2-[[4-(1,1-dimethylethyl)phenyl]thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 1   THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:625349 CAPLUS Full-text
DOCUMENT NUMBER: 145:224321
TITLE: The synthesis and SAR of
                          2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1
                          inhibitors
AUTHOR(S):   Smith, Garrick; Mikkelsen, Gitte; Eskildsen, Jorgen;
                          Bundgaard, Christoffer
CORPORATE SOURCE: Medicinal Chemistry Research, H. Lundbeck A/S, Valby,
                          DK 2500, Den.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),
                          16(15), 3981-3984
                          CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S):   CASREACT 145:224321
GI

AB   Elevation of glycine levels by inhibition of the glycine transporter-1 (GlyT-
      1) and activation of the NMDA receptor is a potential strategy for the
      treatment of schizophrenia. A novel series of 2-arylsulfanylphenyl-1-oxyalkyl
      amino acids have been identified. The most prominent member of this series
      (I) is a potent GlyT-1 inhibitor (IC50 = 59 nM). In vitro and in vivo
      assessment of CNS exposure indicates this compound is a likely substrate for
      active efflux transporters.
IT   791644-20-7P 791644-21-8P
      RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
      SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
      study); PREP (Preparation); USES (Uses)
         (synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1
         inhibitors)
RN   791644-20-7 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-
      (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-21-8 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-
   yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

IT   791642-87-0P 791644-17-2P 791644-18-3P
      794510-03-5P 905815-62-5P 905815-63-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
    (synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1
    inhibitors)
RN   791642-87-0 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-17-2 CAPLUS
CN   L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

RN   791644-18-3 CAPLUS
CN   L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

RN   794510-03-5 CAPLUS
CN   L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

RN   905815-62-5 CAPLUS
CN   D-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   905815-63-6 CAPLUS
CN   L-Proline, 1-[2-[2-chloro-6-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

RN   905815-64-7 CAPLUS
CN   L-Proline, 1-[2-[[4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]-
      (CA INDEX NAME)

Absolute stereochemistry.

RN   905815-65-8 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(3-thienyl)phenoxy]ethyl]-
      (CA INDEX NAME)

Absolute stereochemistry.

RN   905815-66-9 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-methoxy[1,1'-biphenyl]-4-
      yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   905815-67-0   CAPLUS
CN   L-Proline, 1-[2-[[4'-chloro-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-
      yl]oxy]ethyl]-   (CA INDEX NAME)

Absolute stereochemistry.

IT   791642-79-0P 791644-01-4P 905816-02-6P
      905816-03-7P 905816-06-0P 905816-07-1P
      905816-08-2P 905816-09-3P
      RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
      (Reactant or reagent)
         (synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1
         inhibitors)
RN   791642-79-0   CAPLUS
CN   L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester   (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-01-4 CAPLUS
CN   L-Proline, 1-[2-[5-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN   905816-02-6 CAPLUS
CN   D-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN   905816-03-7 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN   905816-06-0   CAPLUS
CN   L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester   (CA INDEX NAME)

Absolute stereochemistry.

RN   905816-07-1   CAPLUS
CN   L-Proline, 1-[2-[2-chloro-6-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester   (CA INDEX NAME)

Absolute stereochemistry.

RN   905816-08-2   CAPLUS
CN   L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester   (CA INDEX NAME)

Absolute stereochemistry.

RN   905816-09-3 CAPLUS
CN   L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 11   THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965214 CAPLUS Full-text
DOCUMENT NUMBER: 141:411217
TITLE: A preparation of oxyphenyl and sulfanylphenyl
                          derivatives of amino acids, useful as glycine
                          transporter inhibitors
INVENTOR(S):   Smith, Garrick Paul; Mikkelsen, Gitte; Andersen, Kim;
                          Greve, Daniel Rodriguez; Eskildsen, Joergen
PATENT ASSIGNEE(S):   H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 87 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

      PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
      ---------------   ----   --------   --------------------   --------
      WO 2004096761   A1   20041111   WO 2004-DK290   20040427
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

```
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
  AU 2004233942        A1     20041111     AU 2004-233942          20040427
  CA 2523585           A1     20041111     CA 2004-2523585         20040427
  EP 1622868           A1     20060208     EP 2004-729612          20040427
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
  BR 2004009739        A      20060509     BR 2004-9739            20040427
  JP 2006524642        T      20061102     JP 2006-504368          20040427
  MX 2005011198        A      20051214     MX 2005-11198           20051018
  IN 2005CN02812       A      20070525     IN 2005-CN2812          20051031
  NO 2005005632        A      20051129     NO 2005-5632            20051129
  US 20060235003       A1     20061019     US 2006-551737          20060606
PRIORITY APPLN. INFO.:                     DK 2003-649        A    20030430
                                           US 2003-466755P    P    20030430
                                           WO 2004-DK290      W    20040427

OTHER SOURCE(S):         MARPAT 141:411217
GI
```



```
AB   The invention relates to a preparation of aromatic oxyphenyl and aromatic
     sulfanylphenyl derivs. of formula I [wherein: X is O, S, or CH2, etc.; Y is O
     or S; R1, R2, R3, and R4 are independently selected from H, halogen, CN, NO2,
     or alk(en/yn)yl, etc.; R5 is (un)substituted aryl or monocyclic heteroaryl; R6
     is H, alk(en/yn)yl, cycloalk(en)yl, or alk(en/yn)ylsulfanyl, etc.; R7 and R8
     are independently selected from H, alk(en/yn)yl, or cycloalk(en)yl; R9 and R11
     are independently selected from H, alk(en/yn)yl, hydroxyalk(en/yn)yl, or
     alk(en/yn)ylsulfanyl, etc.; R10 is H, alk(en/yn)yl, aryl, or arylalk(en/yn)yl,
     etc.; R6 and R8 together with the nitrogen may form 3-7 membered heterocyclic
     ring], useful as glycine transporter inhibitors (IC50 < 10000 nM).  The
     compds. of formula I are useful for the treatment of diseases such as
     schizophrenia, including both the pos. and the neg. symptoms of schizophrenia.
     For instance, pyrrolidinecarboxylic acid derivative II was prepared via
     etherification of 2-(3-fluorophenylsulfanyl)phenol by
     (hydroxyethyl)pyrrolidinecarboxylate derivative III.
IT   791642-79-0P, (S)-1-[2-[4-Bromo-2-(3-
     fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
```

```
      tert-butyl ester
      RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
      (Reactant or reagent)
          (intermediate; preparation of oxyphenyl and sulfanylphenyl derivs. of amino
          acids, useful as glycine transporter inhibitors)
RN    791642-79-0  CAPLUS
CN    L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      1,1-dimethylethyl ester  (CA INDEX NAME)

Absolute stereochemistry.
```



```
IT    791642-81-4P, (S)-1-[2-[2-(4-
      Fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-83-6P, (S)-1-[2-[2-(4-tert-
      Butylphenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-84-7P, (S)-1-[2-[2-(4-
      Trifluoromethylphenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-85-8P, (S)-1-[2-[2-(3-
      Fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-86-9P, (S)-1-[2-[2-(4-Chlorophenylsulfanyl)-phenoxy]-
      ethyl]pyrrolidine-2-carboxylic acid 791642-87-0P,
      (S)-1-[2-[2-(3-Chlorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic
      acid 791642-88-1P, (S)-1-[2-[2-(3,4-
      Dichlorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-90-5P, (S)-1-[2-[2-(3-Chloro-4-
      fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-91-6P, (S)-1-[2-[2-(3-
      Chlorophenoxy)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
      791642-92-7P 791642-93-8P 791642-94-9P
      791642-95-0P 791642-97-2P 791642-98-3P
      791642-99-4P 791643-00-0P 791643-01-1P
      791643-85-1P 791643-88-4P 791643-90-8P
      791643-91-9P 791643-92-0P 791643-94-2P
      791643-95-3P 791643-97-5P 791643-99-7P
      791644-00-3P 791644-02-5P 791644-04-7P
      791644-06-9P 791644-08-1P 791644-09-2P
      791644-15-0P 791644-17-2P 791644-18-3P
      791644-19-4P 791644-20-7P 791644-21-8P
      791644-22-9P 791644-23-0P 791644-24-1P
      791644-25-2P 791644-26-3P 791644-27-4P
      791644-28-5P
      RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
      (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
      (Uses)
          (preparation of oxyphenyl and sulfanylphenyl derivs. of amino acids, useful
          as glycine transporter inhibitors)
```

RN   791642-81-4 CAPLUS
CN   L-Proline, 1-[2-[2-[(4-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-83-6 CAPLUS
CN   L-Proline, 1-[2-[2-[[4-(1,1-dimethylethyl)phenyl]thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

RN   791642-84-7 CAPLUS
CN   L-Proline, 1-[2-[2-[[4-(trifluoromethyl)phenyl]thio]phenoxy]ethyl]- (CA
   INDEX NAME)

Absolute stereochemistry.

RN   791642-85-8 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-86-9   CAPLUS
CN   L-Proline, 1-[2-[2-[(4-chlorophenyl)thio]phenoxy]ethyl]-   (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-87-0   CAPLUS
CN   L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-   (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-88-1   CAPLUS
CN   L-Proline, 1-[2-[2-[(3,4-dichlorophenyl)thio]phenoxy]ethyl]-   (CA INDEX
      NAME)

Absolute stereochemistry.

RN   791642-90-5 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-chloro-4-fluorophenyl)thio]phenoxy]ethyl]- (CA
      INDEX NAME)

Absolute stereochemistry.

RN   791642-91-6 CAPLUS
CN   L-Proline, 1-[2-[2-(3-chlorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-92-7 CAPLUS
CN   L-Proline, 1-[2-[2-(4-chlorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-93-8 CAPLUS
CN   L-Proline, 1-[2-[2-(4-methoxyphenoxy)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-94-9 CAPLUS
CN   L-Proline, 1-[2-[2-(3,4-difluorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-95-0 CAPLUS
CN   L-Proline, 1-[2-[2-(4-chlorophenoxy)phenoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-97-2 CAPLUS
CN   L-Proline, 1-[2-[2-(3,4-difluorophenoxy)phenoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-98-3 CAPLUS
CN   L-Proline, 1-[2-[2-(3-fluorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791642-99-4 CAPLUS
CN   L-Proline, 1-[2-[2-(3-fluorophenoxy)phenoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791643-00-0   CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]phenoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791643-01-1   CAPLUS
CN   L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791643-85-1   CAPLUS
CN   L-Proline, 1-[3-[2-[(3-fluorophenyl)thio]phenyl]propyl]-, hydrochloride
   (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN   791643-88-4 CAPLUS
CN   L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      hydrochloride (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN   791643-90-8 CAPLUS
CN   L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
   hydrochloride (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN   791643-91-9 CAPLUS
CN   L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      hydrochloride (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

●HCl

RN   791643-92-0 CAPLUS
CN   L-Proline, 1-[2-[4-cyano-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-   (CA
   INDEX NAME)

Absolute stereochemistry.

RN   791643-94-2 CAPLUS
CN   L-Proline, 1-[2-[5-chloro-2-(phenylthio)phenoxy]ethyl]-, hydrochloride
      (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

RN   791643-95-3 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-
      , hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN   791643-97-5 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-
      yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

Absolute stereochemistry.

● HCl

Absolute stereochemistry.

Absolute stereochemistry.

Absolute stereochemistry.

●HCl

RN   791644-06-9 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-(methylsulfonyl)[1,1'-
      biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

●HCl

RN   791644-08-1 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(4-morpholinyl)phenoxy]ethyl]-
      , monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN   791644-09-2 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(1-piperidinyl)phenoxy]ethyl]-
      , monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN   791644-15-0 CAPLUS
CN   L-Proline, 1-[3-[2-[(3-fluorophenyl)thio]phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-17-2 CAPLUS
CN   L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
   INDEX NAME)

Absolute stereochemistry.

RN   791644-18-3 CAPLUS
CN   L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
        INDEX NAME)

Absolute stereochemistry.

RN   791644-19-4 CAPLUS
CN   L-Proline, 1-[2-[5-chloro-2-(phenylthio)phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-
        (CA INDEX NAME)

Absolute stereochemistry.

CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-
        yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

CN   L-Proline, 1-[2-[[4'-cyano-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-
        yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-23-0 CAPLUS
CN   L-Proline, 1-[2-[[4'-cyano-4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-
      yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-24-1 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-5-(3-thienyl)phenoxy]ethyl]-
      (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-25-2 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(5-pyrimidinyl)phenoxy]ethyl]-
      (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-26-3 CAPLUS
CN   L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-(methylsulfonyl)[1,1'-
      biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-27-4 CAPLUS
CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(4-morpholinyl)phenoxy]ethyl]-
      (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-28-5 CAPLUS

CN   L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(1-piperidinyl)phenoxy]ethyl]-
         (CA INDEX NAME)

Absolute stereochemistry.

IT   791643-98-6 791644-01-4 791644-07-0
      RL: RCT (Reactant); RACT (Reactant or reagent)
         (reactant; preparation of oxyphenyl and sulfanylphenyl derivs. of amino
         acids, useful as glycine transporter inhibitors)
RN   791643-98-6 CAPLUS
CN   L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
      hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-01-4 CAPLUS
CN   L-Proline, 1-[2-[5-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
   1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN   791644-07-0 CAPLUS
CN   L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, butyl
     ester (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 4   THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                              RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:666715 CAPLUS Full-text
DOCUMENT NUMBER: 133:252449
TITLE: Quinazolines and other bicyclic heterocycles,
                         pharmaceutical compositions containing these compounds
                         as tyrosine kinase inhibitors, and processes for
                         preparing them
INVENTOR(S):   Himmelsbach, Frank; Langkopf, Elke; Blech, Stefan;
                         Jung, Birgit; Metz, Thomas; Solca, Flavio
PATENT ASSIGNEE(S):   Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 153 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
     ---------------   ----   --------   --------------------   --------
     WO 2000055141   A1   20000921   WO 2000-EP2228   20000314
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,

```
          MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
          SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
      RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
          DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
          CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
  DE 19911509          A1    20000921      DE 1999-19911509       19990315
  CA 2368059           A1    20000921      CA 2000-2368059        20000314
  EP 1163227           A1    20011219      EP 2000-909360         20000314
  EP 1163227           B1    20050928
      R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
          IE, SI, LT, LV, FI, RO
  BR 2000009076        A     20011226      BR 2000-9076           20000314
  TR 200102782         T2    20020422      TR 2001-2782           20000314
  JP 2002539199        T     20021119      JP 2000-605571         20000314
  JP 3754617           B2    20060315
  EE 200100484         A     20021216      EE 2001-484            20000314
  EE 5034              B1    20080616
  HU 2002001832        A2    20021228      HU 2002-1832           20000314
  HU 2002001832        A3    20030228
  NZ 514706            A     20031128      NZ 2000-514706         20000314
  AU 772520            B2    20040429      AU 2000-31667          20000314
  CN 1150171           C     20040519      CN 2000-805005         20000314
  AT 305456            T     20051015      AT 2000-909360         20000314
  ES 2250111           T3    20060416      ES 2000-909360         20000314
  IL 144626            A     20070211      IL 2000-144626         20000314
  TW 268924            B     20061221      TW 2000-89104508       20000426
  IN 2001MN00956       A     20050304      IN 2001-MN956          20010809
  MX 2001008324        A     20020311      MX 2001-8324           20010816
  US 20020177601       A1    20021128      US 2001-938235         20010823
  ZA 2001007185        A     20020621      ZA 2001-7185           20010830
  BG 105893            A     20020531      BG 2001-105893         20010912
  BG 65130             B1    20070330
  KR 749292            B1    20070814      KR 2001-711645         20010913
  NO 2001004487        A     20010914      NO 2001-4487           20010914
  HK 1043124           A1    20041203      HK 2002-104697         20020625
  JP 2006077010        A     20060323      JP 2005-259571         20050907
  US 20060063752       A1    20060323      US 2005-266920         20051104
PRIORITY APPLN. INFO.:                     DE 1999-19911509   A   19990315
                                           JP 2000-605571     A3  20000314
                                           WO 2000-EP2228     W   20000314
                                           US 2001-938235     A1  20010823

OTHER SOURCE(S):        MARPAT 133:252449
GI
```

$$\text{I}$$

$$\text{II}$$

AB   The invention relates to bicyclic heterocyclic compds. I [R1 = H, alkyl; R2 =
      (un)substituted Ph, CH2Ph, or CH(Me)Ph; R3, R4 = H, F, Cl, OMe, or Me
      optionally substituted by OMe, NMe2, NEt2, pyrrolidino, piperidino, or
      morpholino; X = N or C(CN); A = O, NH, (un)substituted alkylene, O-alkylene,
      NH-alkylene, O-cycloalkylene, etc.; B = (un)substituted amine-containing
      sidechain, piperazino, alkyleneimino, morpholino, etc.; or AB = H, F, Cl,
      alkoxy, amino, etc.; C = groups similar to A; D = groups similar to B; with a
      variety of provisos] and their tautomers, stereoisomers, and salts, and
      particularly their physiol. acceptable salts with inorg. or organic acids or
      bases. The compds. have valuable pharmacol. properties, particularly an
      inhibitory effect on signal transduction mediated by tyrosine kinases, and are
      useful in treating diseases, particularly tumor diseases, and diseases of the
      lung and airways. Over 20 compds. were prepared, and over 200 are listed.
      For instance, alkylation of 4-(3-chloro-4-fluorophenylamino)-6-[3-(1-
      piperazinyl)propyloxy]-7- methoxyquinazoline (preparation given) by Me
      bromoacetate gave 51% title compound II. The latter compound inhibited EGF-
      dependent proliferation of F/L-HERc cells in vitro, with an IC50 of 46 nM.
IT   295330-27-7P, (R)-4-[(3-Chloro-4-fluorophenyl)amino]-6-[2-[2-
      (methoxycarbonyl)pyrrolidin-1-yl]ethoxy]-7-cyclopentyloxyquinazoline
      RL: BAC (Biological activity or effector, except adverse); BSU (Biological
      study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
      BIOL (Biological study); PREP (Preparation); USES (Uses)
          (drug candidate; preparation of quinazoline derivs. and other bicyclic
          heterocycles as tyrosine kinase inhibitors)
RN   295330-27-7 CAPLUS
CN   D-Proline, 1-[2-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyloxy)-6-
      quinazolinyl]oxy]ethyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5   THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 07:44:30 ON 06 APR 2009